Importance

Loading Importance Indicators...

Abstract

Pyrimidines of formla (1) are described: 1 wherein R.sup.1 is a --XR.sub.6 group; R.sup.2 and R.sup.3 which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, --OH, --OR.sup.10 [where R.sup.10 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group) --SH, --NO.sub.2, --CN, --SR.sup.10, --COR.sup.10, S(O)R.sup.10, --SO.sub.2R.sup.8, --SO.sub.2N(R.sup.8)(R.sup.9), --CO.sub.2R.sup.8, --CON(R.sup.8)(R.sup.9), --CSN(R.sup.8)(R.sup.9), --NH.sub.2 or substituted amino group; R.sup.4 is a X.sup.1R.sup.11 group where X.sup.1 is a covalent bond or a --C(R.sup.12)(R.sup.13)-- [where each of R.sup.12 and R.sup.13 is a hydrogen or halogen atom or a hydroxyl, alkyl or haloalkyl group] or --C(O)-- group and R.sup.11 is an optionally substituted phenyl, thienyl, thiazolyl or indolyl group; R.sup.5 is a halogen atom or an alkynyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis

Loading the Abstract Image...

First Claim